73/100BIf you had invested in ABBVIE ago, it would be worth $7,906 today, against $4,305 in SPY and $6,524 in QQQ.
Arincen ScoreBeta
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
ABBVIE key facts
- Style
- Growth stock · 6.1/10Growth 6.1 · Value 3.6 · Dividend 4.7
- Day range
- 283.32 – 295.38
- 52-week range
- 190.75 – 298.74
- Market capitalization
- 521.05B USD
- P/E
- 50.58
- EPS
- 5.83
- Div Yield
- 2.47%
- EPS growth forecast (FY2026)
- +39.7%
- Volume
- 275,608
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael
- Employees
- 57K
- Website
- abbvie.com
- IPO date
- 2 Jan 2013
ABBVIE earnings
Revenue
EPS
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2028 | 4.51 | — | — | — | 19.67B | — | — | — | |
| Q1 FY2028 | 4.04 | — | — | +17.68% | 18.58B | — | — | +12.55% | |
| Q1 FY2027 | 3.43 | — | — | +29.39% | 16.51B | — | — | +10.05% | |
| Q4 FY2026 | 3.89 | — | — | +43.54% | 18.33B | — | — | +10.29% | |
| Q3 FY2026 | 3.73 | 3.82 | +2.41% | +105.38% | 17.32B | 17.40B | +0.51% | +10.32% | |
| Q2 FY2026 | 3.61 | 3.65 | +1.11% | +22.90% | 16.80B | 16.99B | +1.11% | +10.16% | |
| Q1 FY2026 | 2.59 | 2.65 | +2.32% | +7.72% | 14.72B | 15.00B | +1.93% | +12.43% | |
| Q4 FY2025 | 2.65 | 2.71 | +2.26% | +25.46% | 16.41B | 16.62B | +1.25% | +10.04% | |
| Q3 FY2025 | 1.77 | 1.86 | +5.08% | -38.00% | 15.59B | 15.78B | +1.22% | +9.10% | |
| Q2 FY2025 | 2.88 | 2.97 | +3.13% | +12.08% | 15.03B | 15.42B | +2.62% | +6.65% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 18.00 | — | — | +10.36% | 79.40B | — | — | +7.78% |
| FY2027 | 16.31 | — | — | +16.76% | 73.67B | — | — | +8.87% |
| FY2026 | 13.97 | — | — | +39.70% | 67.67B | — | — | +10.64% |
| FY2025 | 9.94 | 10.00 | +0.61% | -1.19% | 60.97B | 61.16B | +0.32% | +8.57% |
| FY2024 | 10.08 | 10.12 | +0.37% | -8.91% | 56.04B | 56.33B | +0.52% | +3.71% |
| FY2023 | 11.13 | 11.11 | -0.19% | -19.90% | 54.05B | 54.32B | +0.50% | -6.44% |
| FY2022 | 13.76 | 13.87 | +0.77% | +9.21% | 58.27B | 58.05B | -0.37% | +3.30% |
ABBVIE analyst forecast
Analysts' 1-year price targets range from 235.00 to 340.00, with an average of 308.88.
| Strong buy | 0 | |
| Buy | 21 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 340.00 |
| Average target | 308.88 |
| Lowest target | 235.00 |
| Current price | 294.86 |
ABBVIE valuation
- Price to earnings ratio (TTM)
- 50.58
- Forward P/E (FY2026)
- 21.11
- Price to sales (TTM)
- 7.89
- Price to book
- 17.30
- EV / EBITDA (TTM)
- 24.48
Capital structure
Valuation over time
ABBVIE against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Johnson & Johnson, Merck & Co., Amgen, Gilead Sciences, Eli Lilly and, and Pfizer, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median50.618.9177.5
- Gross marginHighest in 5 years70.2%62.4%70.2%Against its peers: 6 of 7Peers' median 73.2%
- Operating marginHighest in 5 years32.8%16.2%32.8%Against its peers: 4 of 7Peers' median 32.6%
- Net marginLowest in 5 years6.9%6.9%20.5%Against its peers: 7 of 7Peers' median 28.3%
- Free cash flow marginLowest in 5 years29.1%29.1%41.8%Against its peers: 2 of 7Peers' median 20.0%
- Revenue growthAbove its median8.6%-6.4%22.7%Against its peers: 3 of 7Peers' median 4.2%
- EPS growthAt its median-0.8%-59.0%137.1%Against its peers: 6 of 7Peers' median 89.4%
- Debt to EBITDAAbove its median3.92×2.66×4.55×Against its peers: 6 of 7Peers' median 1.81×
- Current ratioBelow its median0.670.660.96Against its peers: 7 of 7Peers' median 1.35
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
ABBVIE growth and profitability
- Revenue (TTM)
- 66.01B USD
- Net income (TTM)
- 10.35B USD
- Gross margin
- 76.25%
- Operating margin
- 35.53%
- Net margin
- 15.68%
Revenue / Net income
ABBVIE revenue breakdown
By product
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| SKYRIZI | 17.56B | 30.2% | +49.9% |
| RINVOQ | 8.30B | 14.3% | +39.1% |
| H U M I R A | 4.54B | 7.8% | -49.5% |
| Botox Therapeutic | 3.77B | 6.5% | +14.8% |
| Vraylar | 3.62B | 6.2% | +10.8% |
| Imbruvica | 2.87B | 4.9% | -14.3% |
| VENCLEXTA | 2.79B | 4.8% | +8.1% |
| Other Products | 2.63B | 4.5% | -13.4% |
| Botox Cosmetic | 2.60B | 4.5% | -4.3% |
| MAVYRET | 1.32B | 2.3% | +0.5% |
| Ubrelvy | 1.27B | 2.2% | +26.3% |
| Other Aesthetics | 1.27B | 2.2% | -1.1% |
| Qulipta | 1.04B | 1.8% | +57.4% |
| Other Eye Care | 1.01B | 1.7% | +19.1% |
| Juvederm Collection | 993.00M | 1.7% | -15.6% |
| Linzess/Constella | 907.00M | 1.6% | -4.9% |
| Ozurdex | 493.00M | 0.8% | -0.2% |
| Lumigan/Ganfort | 410.00M | 0.7% | -4.4% |
| Duodopa | 381.00M | 0.7% | -14.8% |
| Other Neuroscience | 207.00M | 0.4% | -38.8% |
| Alphagan/Combigan | 197.00M | 0.3% | -20.6% |
By region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| UNITED STATES | 46.60B | 95.2% | +8.3% |
| Non-US | 2.36B | 4.8% | -82.2% |
How ABBVIE makes its money
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
ABBVIE dividends
- Annual dividend
- 7.28 USD
- Dividend yield (indicated)
- 2.47%
- Payout ratio
- 149.91%
- Years of dividend growth
- 13
- Frequency
- Quarterly
- Last payment
- 1.82 USD
- Last ex-dividend date
- 15 Jan 2027
- Last payment date
- 16 Feb 2027
Dividends per share
ABBVIE financial health
- Cash and short-term investments
- 10.77B USD
- Total debt
- 80.90B USD
- Net cash
- -70.13B USD
- Free cash flow (TTM)
- 19.76B USD
- Current ratio
- 0.87
- Debt to equity
- 2.69
- Piotroski score
- 8 / 9
- Altman Z-score
- 3.25
Cash, debt and free cash flow
ABBVIE ownership
- Institutions
- 76.07%
- Institutional holders
- 4,353 (+130)
- Free float
- 99.82%
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q3 2026 | 0 | 1 | 32.90K | 65.42K |
| Q2 2026 | 0 | 0 | 12.49K | 0.00 |
| Q1 2026 | 0 | 5 | 564.06K | 209.10K |
| Q4 2025 | 0 | 0 | 249.00 | 0.00 |
Shares outstanding
Source: Financial Modeling Prep
